These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

769 related articles for article (PubMed ID: 9210715)

  • 41. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL.
    Stephan C; Stroebel G; Heinau M; Lenz A; Roemer A; Lein M; Schnorr D; Loening SA; Jung K
    Cancer; 2005 Sep; 104(5):993-1003. PubMed ID: 16007682
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inadequacy of free prostate-specific antigen parameters in the prediction of pathologic extent of prostate cancer in Japanese men.
    Egawa S; Suyama K; Soh S; Kuwao S; Uchida T; Koshiba K
    Urology; 1998 Aug; 52(2):230-6. PubMed ID: 9697787
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The value of PSA, free-to-total PSA ratio and PSA density in the prediction of pathologic stage for clinically localized prostate cancer.
    Aslan G; Irer B; Kefi A; Celebi I; Yörükoğlu K; Esen A
    Int Urol Nephrol; 2005; 37(3):511-4. PubMed ID: 16307332
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy.
    Giesing M; Suchy B; Driesel G; Molitor D
    BJU Int; 2010 Apr; 105(7):1000-10. PubMed ID: 19818074
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prostate specific antigen density of the transition zone for predicting pathological stage of localized prostate cancer in patients with serum prostate specific antigen less than 10 ng./ml.
    Zlotta AR; Djavan B; Petein M; Susani M; Marberger M; Schulman CC
    J Urol; 1998 Dec; 160(6 Pt 1):2089-95. PubMed ID: 9817330
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy.
    Graefen M; Karakiewicz PI; Cagiannos I; Hammerer PG; Haese A; Palisaar J; Huland E; Scardino PT; Kattan MW; Huland H
    J Urol; 2002 Mar; 167(3):1306-9. PubMed ID: 11832719
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical and pathologic predictors of Gleason sum upgrading in patients after radical prostatectomy: results from a single institution series.
    Tilki D; Schlenker B; John M; Buchner A; Stanislaus P; Gratzke C; Karl A; Tan GY; Ergün S; Tewari AK; Stief CG; Seitz M; Reich O
    Urol Oncol; 2011; 29(5):508-14. PubMed ID: 19837614
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Values of prostate specific antigen in patients with operable prostate carcinoma.
    Obralic N; Kulovac B; Aganovic D; Junuzovic D
    Med Arh; 2009; 63(1):34-7. PubMed ID: 19419125
    [TBL] [Abstract][Full Text] [Related]  

  • 49. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The role of (
    Yilmaz U; Komek H; Can C; Altindag S
    Ann Nucl Med; 2019 Aug; 33(8):545-553. PubMed ID: 31069696
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
    Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
    BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predictors of prostate-specific antigen progression among men with seminal vesicle invasion at the time of radical prostatectomy.
    Freedland SJ; Aronson WJ; Presti JC; Amling CL; Terris MK; Trock B; Kane CJ
    Cancer; 2004 Apr; 100(8):1633-8. PubMed ID: 15073850
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
    Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
    J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prostate health index density predicts aggressive pathological outcomes after radical prostatectomy in Taiwanese patients.
    Huang YP; Lin TP; Cheng WM; Wei TC; Huang IS; Fan YH; Lin CC; Huang EYH; Chung HJ; Kuo JY; Wu HHH; Lu SH; Chang YH; Lin ATL; Huang WJS
    J Chin Med Assoc; 2019 Nov; 82(11):835-839. PubMed ID: 31425303
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
    Kupelian P; Katcher J; Levin H; Zippe C; Klein E
    Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic value of three molecular forms of prostate-specific antigen ratios in patients with prostate adenocarcinoma.
    Okegawa T; Kato M; Nutahara K; Higashihara E
    Urology; 2001 May; 57(5):936-42. PubMed ID: 11337298
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial.
    Southwick PC; Catalona WJ; Partin AW; Slawin KM; Brawer MK; Flanigan RC; Patel A; Richie JP; Walsh PC; Scardino PT; Lange PH; Gasior GH; Parson RE; Loveland KG
    J Urol; 1999 Oct; 162(4):1346-51. PubMed ID: 10492194
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of molecular forms of prostate-specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomy.
    Wenske S; Korets R; Cronin AM; Vickers AJ; Fleisher M; Scher HI; Pettersson K; Guillonneau B; Scardino PT; Eastham JA; Lilja H
    Int J Cancer; 2009 Feb; 124(3):659-63. PubMed ID: 19003994
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers.
    Noguchi M; Stamey TA; McNeal JE; Yemoto CM
    J Urol; 2000 Nov; 164(5):1596-600. PubMed ID: 11025712
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of preoperative prostate specific antigen density and prostate specific antigen for predicting recurrence after radical prostatectomy: results from the search data base.
    Freedland SJ; Kane CJ; Presti JC; Terris MK; Amling CL; Dorey F; Aronson WJ
    J Urol; 2003 Mar; 169(3):969-73. PubMed ID: 12576824
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.